AR and prostate carcinoma: More importantly, we demonstrated a synergy of combination of curcumin and bicalutamide, the androgen receptor antagonist, in the inhibition of p65, MUC1-C and androgen-independent prostate cancer cell growth, implying that signaling and mechanisms other than through the AR-mediated regulatory pathways and genes contributed to the overall enhanced effects.